Lakeshore Biopharma Co.LSBCF
13F holders, Q4 2024 (December 31)6holders
$3.45avg. 13F price*
At the end of Q4 2024, 6 institutions reported holding Lakeshore Biopharma Co. Ltd. (LSBCF) in their 13F filings. The largest holders were Orbimed Advisors LLC ($486K), FMR LLC ($402K) and HHLR Advisors, LTD. ($259K).
- Company
- Lakeshore Biopharma Co. Ltd.
- CUSIP
- G9845F208
- Latest filing quarter
- Q3 2025
History
Number of 13F holders
Total Exit/New Position Q4 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 1 | $486K |
| Exits | 0 | $0 |
Ownership 6 holders
| Orbimed Advisors LLC | 0.01% | New | 140,428 | $486K |
| FMR LLC | 0.00% | No change | 116,508 | $402K |
| HHLR Advisors, LTD. | 0.01% | No change | 75,179 | $259K |
| Superstring Capital Management LP | 0.09% | No change | 30,792 | $106K |
| Barclays PLC | 0.00% | No change | 24,757 | $86K |
| UBS Group AG | 0.00% | Reduce -81.0% | 940 | $3K |
"% of holder's portfolio" is LSBCF's weight in each manager's 13F, not the share of Lakeshore Biopharma Co. Ltd. the manager owns.